Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShort-Term Debt issuances
Growth Metrics
Income Statement
Others
Ratios

Coeptis Therapeutics Holdings (COEPW) Free Cash Flow (2021 - 2025)

Coeptis Therapeutics Holdings has reported Free Cash Flow over the past 5 years, most recently at -$1.7 million for Q4 2025.

  • Quarterly results put Free Cash Flow at -$1.7 million for Q4 2025, down 17.5% from a year ago — trailing twelve months through Dec 2025 was -$8.6 million (down 29.38% YoY), and the annual figure for FY2025 was -$8.6 million, down 29.38%.
  • Free Cash Flow for Q4 2025 was -$1.7 million at Coeptis Therapeutics Holdings, up from -$2.2 million in the prior quarter.
  • Over the last five years, Free Cash Flow for COEPW hit a ceiling of -$59847.0 in Q3 2021 and a floor of -$4.2 million in Q4 2021.
  • Median Free Cash Flow over the past 5 years was -$1.7 million (2023), compared with a mean of -$1.5 million.
  • Peak annual rise in Free Cash Flow hit 79.66% in 2022, while the deepest fall reached 1626.42% in 2022.
  • Coeptis Therapeutics Holdings' Free Cash Flow stood at -$4.2 million in 2021, then skyrocketed by 79.66% to -$847352.0 in 2022, then crashed by 99.89% to -$1.7 million in 2023, then increased by 15.19% to -$1.4 million in 2024, then fell by 17.5% to -$1.7 million in 2025.
  • The last three reported values for Free Cash Flow were -$1.7 million (Q4 2025), -$2.2 million (Q3 2025), and -$2.4 million (Q2 2025) per Business Quant data.